Other Events ·
Tiziana Life Sciences announced that the last patient completed their final visit in the Phase 2a INFORM-MS clinical…
TLSATiziana Life Sciences Ltd
Tiziana Life Sciences announced that the last patient completed their final visit in the Phase 2a INFORM-MS clinical trial evaluating intranasal foralumab for non-active Secondary Progressive Multiple Sclerosis. The randomized, double-blind study enrolled 48 patients across three cohorts to assess safety and efficacy over a 12-week period. The company expects to lock the database immediately and release topline data in October. Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing immunomodulation therapies using intranasal drug delivery technologies.